Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Creative Medical Shares Soar On Positive Data from StemSpine Pilot Study

  • Creative Medical Technology Holdings (NASDAQ:CELZ) has announced positive two-year follow-up data from its StemSpine pilot study.
  • The data showed significant efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects reported.
  • StemSpine is a patented procedure that utilizes a patient's bone marrow aspirate to treat chronic lower back pain.
  • There were no safety-related concerns for up to two years, and the StemSpine procedure resulted in an efficacy rate of 87% in the treated patients. 
  • The Company plans to submit a manuscript for publication in a peer-reviewed journal and present the data at future orthopedic/sports medicine conferences. 
  • Price Action: CELZ shares are up 80.30% at $3.07 on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.